Valion Bio (VBIO) Common Equity (2021 - 2026)

Valion Bio has reported Common Equity for 6 years, with the latest figure at $4.2 million in Q2 2026.

• On a quarterly basis, Common Equity rose 15.16% year-over-year to $4.2 million in Q2 2026; TTM through Jun 2026 was $4.2 million, a 15.16% increase from a year earlier, with the FY2025 full-year figure at $16.8 million, up 562.6% from the prior year.
• Common Equity was $4.2 million for Q2 2026 at Valion Bio, down from $16.8 million in the prior quarter.
• The five-year high for Common Equity was $16.8 million in Q4 2025, with the low at $2.2 million in Q1 2024.
• Average Common Equity over 5 years is $5.3 million, with a median of $3.7 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2025: Common Equity tumbled 72.65% in 2022, then soared 562.6% in 2025.
• Over 5 years, Common Equity stood at $3.6 million in 2022, then retreated by 1.38% to $3.6 million in 2023, then fell by 29.19% to $2.5 million in 2024, then jumped by 562.6% to $16.8 million in 2025, then plunged by 74.72% to $4.2 million in 2026.
• The last three Common Equity figures came in at $4.2 million (Q2 2026), $16.8 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.